XML 21 R12.htm IDEA: XBRL DOCUMENT
v3.23.3

Revenue from contracts with customers | 9 Months Ended
--- | ---
Sep. 30, 2023
Revenue from contracts with customers | NOTE 3 – Revenue from contracts with customers: Disaggregation of revenue The following table disaggregates Teva’s revenues by major revenue streams. For additional information on disaggregation of revenues, see note 15.
|  | Three months ended September 30, 2023 |
|  | North America |  |  | Europe |  |  | International Markets |  |  | Other activities |  |  | Total |
|  | (U.S.$ in millions) |
Sale of goods |  |  | 1,603 |  |  |  | 1,117 |  |  |  | 453 |  |  |  | 130 |  |  |  | 3,303 |
Licensing arrangements |  |  | 31 |  |  |  | 13 |  |  |  | 8 |  |  |  | 1 |  |  |  | 53 |
Distribution |  |  | 367 |  |  |  | § |  |  |  | 9 |  |  |  | — |  |  |  | 377 |
Other |  |  | § |  |  |  | 15 |  |  |  | 15 |  |  |  | 86 |  |  |  | 117 |
|  | $ | 2,002 |  |  | $ | 1,146 |  |  | $ | 485 |  |  | $ | 217 |  |  | $ | 3,850 |
§ | Represents an amount less than $0.5 million.
|  | Three months ended September 30, 2022 |
|  | North America |  |  | Europe |  |  | International Markets |  |  | Other activities |  |  | Total |
|  | (U.S.$ in millions) |
Sale of goods |  |  | 1,393 |  |  |  | 1,034 |  |  |  | 445 |  |  |  | 149 |  |  |  | 3,021 |
Licensing arrangements |  |  | 37 |  |  |  | 10 |  |  |  | 4 |  |  |  | 1 |  |  |  | 52 |
Distribution |  |  | 371 |  |  |  | § |  |  |  | 12 |  |  |  | — |  |  |  | 383 |
Other |  |  | 9 |  |  |  | 26 |  |  |  | 14 |  |  |  | 91 |  |  |  | 139 |
|  | $ | 1,809 |  |  | $ | 1,069 |  |  | $ | 475 |  |  | $ | 241 |  |  | $ | 3,595 |
§ | Represents an amount less than $0.5 million.
|  | Nine months ended September 30, 2023 |
|  | North America |  |  | Europe |  |  | International Markets |  |  | Other activities |  |  | Total |
|  | (U.S.$ in millions) |
Sale of goods |  |  | 4,500 |  |  |  | 3,446 |  |  |  | 1,365 |  |  |  | 412 |  |  |  | 9,724 |
Licensing arrangements |  |  | 75 |  |  |  | 38 |  |  |  | 18 |  |  |  | 4 |  |  |  | 134 |
Distribution |  |  | 1,183 |  |  |  | § |  |  |  | 29 |  |  |  | — |  |  |  | 1,212 |
Other |  |  | § |  |  |  | 8 |  |  |  | 44 |  |  |  | 265 |  |  |  | 318 |
|  | $ | 5,759 |  |  | $ | 3,493 |  |  | $ | 1,456 |  |  | $ | 681 |  |  | $ | 11,389 |
§ | Represents an amount less than $0.5 million.
|  | Nine months ended September 30, 2022 |
|  | North America |  |  | Europe |  |  | International Markets |  |  | Other activities |  |  | Total |
|  | (U.S.$ in millions) |
Sale of goods |  |  | 4,308 |  |  |  | 3,295 |  |  |  | 1,338 |  |  |  | 505 |  |  |  | 9,447 |
Licensing arrangements |  |  | 111 |  |  |  | 36 |  |  |  | 12 |  |  |  | 3 |  |  |  | 162 |
Distribution |  |  | 1,021 |  |  |  | 1 |  |  |  | 38 |  |  |  | — |  |  |  | 1,060 |
Other |  |  | 10 |  |  |  | 65 |  |  |  | 33 |  |  |  | 266 |  |  |  | 373 |
|  | $ | 5,450 |  |  | $ | 3,396 |  |  | $ | 1,422 |  |  | $ | 773 |  |  | $ | 11,041 |
Variable consideration Variable consideration mainly includes sales reserves and allowances (“SR&A”), comprised of rebates (including Medicaid and other governmental program discounts), chargebacks, returns and other promotional (including shelf stock adjustments) items. Provisions for prompt payment discounts are netted against accounts receivables. The Company recognizes these provisions at the time of sale and adjusts them if the actual amounts differ from the estimated provisions. SR&A to U.S. customers comprised approximately 66% of the Company’s total SR&A as of September 30, 2023, with the remaining balance primarily related to customers in Canada and Germany. The changes in SR&A for third-party sales for the nine months ended September 30, 2023 and 2022 were as follows:
|  | Sales Reserves and Allowances |
|  | Reserves included in Accounts Receivable, net |  |  | Rebates |  |  | Medicaid and other governmental allowances |  |  | Chargebacks |  |  | Returns |  |  | Other |  |  | Total reserves included in Sales Reserves and Allowances |  |  | Total |
|  | (U.S.$ in millions) |
Balance at January 1, 2023 |  | $ | 67 |  |  | $ | 1,575 |  |  | $ | 663 |  |  | $ | 991 |  |  | $ | 455 |  |  | $ | 66 |  |  | $ | 3,750 |  |  | $ | 3,817 |
Provisions related to sales made in current year period |  |  | 262 |  |  |  | 2,968 |  |  |  | 468 |  |  |  | 5,636 |  |  |  | 205 |  |  |  | 73 |  |  |  | 9,350 |  |  |  | 9,612 |
Provisions related to sales made in prior periods |  |  | — |  |  |  | (22 | ) |  |  | (33 | ) |  |  | (21 | ) |  |  | 24 |  |  |  | — |  |  |  | (52 | ) |  |  | (52 | )
Credits and payments |  |  | (268 | ) |  |  | (2,989 | ) |  |  | (617 | ) |  |  | (5,768 | ) |  |  | (251 | ) |  |  | (53 | ) |  |  | (9,678 | ) |  |  | (9,946 | )
Translation differences |  |  | — |  |  |  | (8 | ) |  |  | (2 | ) |  |  | (3 | ) |  |  | — |  |  |  | (6 | ) |  |  | (19 | ) |  |  | (19 | )
Balance at September 30, 2023 |  | $ | 61 |  |  | $ | 1,524 |  |  | $ | 479 |  |  | $ | 835 |  |  | $ | 433 |  |  | $ | 80 |  |  | $ | 3,351 |  |  | $ | 3,412 |
|  | Sales Reserves and Allowances |
|  | Reserves included in Accounts Receivable, net |  |  | Rebates |  |  | Medicaid and other governmental allowances |  |  | Chargebacks |  |  | Returns |  |  | Other |  |  | Total reserves included in Sales Reserves and Allowances |  |  | Total |
|  | (U.S.$ in millions) |
Balance at January 1, 2022 |  | $ | 68 |  |  | $ | 1,655 |  |  | $ | 854 |  |  | $ | 1,085 |  |  | $ | 535 |  |  | $ | 112 |  |  | $ | 4,241 |  |  | $ | 4,309 |
Provisions related to sales made in current year period |  |  | 269 |  |  |  | 2,832 |  |  |  | 684 |  |  |  | 5,656 |  |  |  | 219 |  |  |  | 226 |  |  |  | 9,617 |  |  |  | 9,886 |
Provisions related to sales made in prior periods |  |  | — |  |  |  | (103 | ) |  |  | (15 | ) |  |  | (28 | ) |  |  | (9 | ) |  |  | (3 | ) |  |  | (158 | ) |  |  | (158 | )
Credits and payments |  |  | (285 | ) |  |  | (2,845 | ) |  |  | (762 | ) |  |  | (5,826 | ) |  |  | (300 | ) |  |  | (213 | ) |  |  | (9,946 | ) |  |  | (10,231 | )
Translation differences |  |  | — |  |  |  | (66 | ) |  |  | (11 | ) |  |  | (17 | ) |  |  | (8 | ) |  |  | (4 | ) |  |  | (106 | ) |  |  | (106 | )
Balance at September 30, 2022 |  | $ | 52 |  |  | $ | 1,473 |  |  | $ | 750 |  |  | $ | 870 |  |  | $ | 437 |  |  | $ | 118 |  |  | $ | 3,648 |  |  | $ | 3,700 |
Pledged accounts receivables Accounts receivables, net of allowance for credit losses, include $586 million and $436 million as of September 30, 2023 and December 31, 2022, respectively, which are pledged to PNC Bank, National Association in connection with the U.S. securitization program entered into in November 2022. See note 8f to the consolidated financial statements included in this Quarterly Report on Form 10-Q and note 10f to the consolidated financial statements for the year ended December 31, 2022, included in Teva’s Annual Report on F orm 10-K.

X
- Definition The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-9 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-10 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-15 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-13 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Topic 606 -Publisher FASB -URI https://asc.fasb.org//606/tableOfContent + Details
Name: | us-gaap_RevenueFromContractWithCustomerTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration